French practical guidelines for the diagnosis and management of AA amyloidosis.

[1]  S. Georgin-lavialle,et al.  Identification of factors for persistence of AA amyloidosis in patients with Familial Mediterranean Fever. , 2022, European journal of internal medicine.

[2]  K. Hodaňová,et al.  A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis. , 2021, Kidney international.

[3]  J. Lega,et al.  VEXAS syndrome-related AA amyloidosis: a case report. , 2021, Rheumatology.

[4]  C. Sjöwall,et al.  Successful Treatment of AA Amyloidosis in Ankylosing Spondylitis Using Tocilizumab: Report of Two Cases and Review of the Literature , 2021, Frontiers in Medicine.

[5]  J. Mullikin,et al.  Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. , 2020, The New England journal of medicine.

[6]  S. Georgin-lavialle,et al.  Cause of death and risk factors for mortality in AA amyloidosis: A French retrospective study. , 2020, European journal of internal medicine.

[7]  S. Georgin-lavialle,et al.  The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review , 2020, Frontiers in Immunology.

[8]  B. Hazenberg,et al.  Causes of AA amyloidosis: a systematic review , 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[9]  J. Capeau,et al.  Validation of the usual values provided by a supplier without access to a control population: example of serum amyloid A. , 2019, Annales de biologie clinique.

[10]  R. Papa,et al.  Secondary, AA, Amyloidosis. , 2018, Rheumatic diseases clinics of North America.

[11]  S. Dietrich,et al.  Obesity is a significant susceptibility factor for idiopathic AA amyloidosis , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[12]  S. Georgin-lavialle,et al.  [Familial Mediterranean fever]. , 2018, La Revue de medecine interne.

[13]  Katia Stankovic Stojanovic,et al.  [AA amyloidosis]. , 2021, Nephrologie & therapeutique.

[14]  G. Hatemi,et al.  Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy , 2017, Medicine.

[15]  P. Hawkins,et al.  Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[16]  S. Amselem,et al.  AA amyloidosis is an emerging cause of nephropathy in obese patients. , 2017, European journal of internal medicine.

[17]  N. Takahashi,et al.  Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience , 2017, Clinical and Experimental Nephrology.

[18]  P. Hawkins,et al.  Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. , 2015, Clinical and experimental rheumatology.

[19]  O. Ozyuncu,et al.  Pregnancy outcome of five patients with renal amyloidosis regarding familial Mediterranean fever , 2014, Renal failure.

[20]  P. Hawkins,et al.  Renal Transplantation in Systemic Amyloidosis—Importance of Amyloid Fibril Type and Precursor Protein Abundance , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  G. Merlini,et al.  AA amyloidosis: basic knowledge, unmet needs and future treatments. , 2012, Swiss medical weekly.

[22]  G. Choukroun,et al.  Renal Transplantation in Patients With AA Amyloidosis Nephropathy: Results From a French Multicenter Study , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  Caroline A Sabin,et al.  Natural history and outcome in systemic AA amyloidosis. , 2007, The New England journal of medicine.

[24]  B. Hazenberg,et al.  Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis , 2007, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[25]  E. Ben-Chetrit,et al.  Reproductive system in familial Mediterranean fever: an overview , 2003, Annals of the rheumatic diseases.

[26]  M. Usta,et al.  Long-term Effects of Losartan on Proteinuria and Renal Function in Patients with Renal Amyloidosis , 2002, Scandinavian journal of urology and nephrology.

[27]  L. Lovat,et al.  Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein , 2001, The Lancet.

[28]  R. Çetinkaya,et al.  Effect of Losartan Treatment on the Proteinuria in Normotensive Patients Having Proteinuria due to Secondary Amyloidosis , 2001, Upsala journal of medical sciences.

[29]  O. Rabinovitch,et al.  The Effect of Pregnancy on Renal Function in Amyloidosis of Familial Mediterranean Fever , 1992, American journal of reproductive immunology.